Birkeland KI, et al. - In patients with dysglycemia with vs without anti-glutamic acid dehydrogenase (GAD) antibodies in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, researchers assessed cardiovascular and other outcomes. Out of 12,537 participants, 8,162 had anti-GAD measured at baseline and 267 were anti-GAD positive. Findings revealed a similar incidence of cardiovascular outcomes in anti-GAD positive patients and negative anti-GAD patients, and early insulin treatment had a neutral effect on important outcomes in anti-GAD positive individuals vs standard anti-hyperglycemic treatment. More anti-GAD positive participants had diabetes at inclusion, but no differences in duration of diabetes, age at diagnosis, or ethnic distribution was seen between negative and anti-GAD positive individuals.